Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

M. DAI, Tsu-Yi Chao, T. Chao, C. Chiu, Y. Lu, H. Shiah, Y. Wu, G. Gerald Fetterly, N. Hung, D.L. Cutler, R. Kwan, D. Douglas Kramer, W. Chan, T. Hung

Research output: Contribution to journalArticle

Abstract

Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.
Original languageEnglish
JournalAnnals of Oncology
Publication statusPublished - Oct 21 2018

    Fingerprint

Cite this

DAI, M., Chao, T-Y., Chao, T., Chiu, C., Lu, Y., Shiah, H., Wu, Y., Gerald Fetterly, G., Hung, N., Cutler, D. L., Kwan, R., Douglas Kramer, D., Chan, W., & Hung, T. (2018). Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients. Annals of Oncology.